ImmunityBio reports Phase 3 ANKTIVA-plus-BCG results
The company reported 84% cystectomy avoidance at three years and complete responses beyond 53 months in BCG-unresponsive NMIBC with CIS, with or without papillary tumors.
The company reported 84% cystectomy avoidance at three years and complete responses beyond 53 months in BCG-unresponsive NMIBC with CIS, with or without papillary tumors.